YS Biopharma Co., Ltd. approved the appointment of Dr. Hui Shao, the then-current Chief Executive Officer of the Company, as the Chief Business Officer of the Company, each effective on May 2, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6545 USD | +9.08% |
|
-5.16% | +28.08% |
06-18 | LakeShore Biopharma Co., Ltd Announces Chief Financial Officer Changes | CI |
06-18 | LakeShore Biopharma Co., Ltd Announces Resignation of Zengjun Xu as Director | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.08% | 123M | |
+2.59% | 93.98B | |
-3.42% | 37.69B | |
-12.43% | 32.99B | |
+75.98% | 28.27B | |
-11.70% | 16.17B | |
+1.53% | 14.33B | |
-12.82% | 11.44B | |
+190.36% | 10.96B | |
-54.07% | 9.26B |
- Stock Market
- Equities
- LSB Stock
- News LakeShore Biopharma Co., Ltd
- YS Biopharma Co., Ltd. Approves the Appointment of Hui Shao as the Chief Business Officer